自己注射薬市場：タイプ、用途、流通チャネル、治療分野用途別-世界予測2024-2030年

自己注射薬市場規模は2023年に540億米ドルと推計され、2024年には606億4,000万米ドルに達し、CAGR 12.72%で2030年には1,248億7,000万米ドルに達すると予測されています。

自己注射薬とは、医療従事者の手を借りずに、自分自身で筋肉内、皮下、静脈内に薬剤を投与するために使用される製品を指します。自己注射薬は、糖尿病のインスリン、ホルモン補充療法や不妊治療のホルモン剤、慢性疾患の生物学的製剤など、定期的かつ長期的なケアが必要な治療に使用されます。自己注射器は、自律性を高めるために広く使用されており、ヘルスケア提供者による投与の必要性をなくすことで治療アドヒアランスを向上させることができます。慢性疾患の増加、在宅ヘルスケアの必要性、ドラッグデリバリー技術の進歩、自己注射を好む患者の増加により、近年自己注射薬の使用率は向上しています。しかし、研究開発に多額の投資が必要なこと、患者の安全性と快適性に関する懸念、生物製剤のコールドチェーン保管と物流の必要性などが、自己注射薬の製品浸透を制限しています。デジタル化と患者中心主義の認識により、自己注射機器にスマート技術を統合する機会が生まれます。コネクティビティに焦点を当てた技術革新は、データ収集、患者モニタリング、アドヒアランス追跡を提供し、自己注射薬の個別化治療法を導くことができます。さらに、自己注射薬に対する政府の支持的な承認は、市場の範囲をさらに拡大しています。

タイプ慢性疾患管理のためのペン型注射器への嗜好の高まり

自動注射器は便利に使えるように設計されており、最小限の訓練で正確な量の薬剤を投与できます。自動注射器は、緊急時の救命ドラッグデリバリーに使用されます。自動注射器は、即時かつ確実な薬剤投与を必要とする患者の間でニーズが高く、多くの場合、ヘルスケア専門家の支援を必要としません。無針注射器は、従来の注射器による注射に代わるもので、注射針を必要としないです。無針注射器は、注射液の高圧で細いジェットを皮膚に浸透させ、薬剤を投与します。注射針恐怖症の方は主に無針注射器を好んで使用し、糖尿病患者のように頻繁に注射を必要とする方は、注射針による疲労を経験する可能性があります。ペン型注射器は慢性疾患の管理に広く使用されており、インスリンや成長ホルモンの自己投与が可能です。ペン型注射器は持ち運びが可能で、目立たず、比較的簡単に使用できるため、活動的なライフスタイルを維持しながら定期的に薬剤を投与する必要がある患者にとって魅力的です。パッチポンプとしても知られるウェアラブル注射器は、患者の体に密着し、長期間にわたってドラッグデリバリーを継続的または制御する装置です。ウェアラブル注射器は、主に長期の治療が必要な患者に使用されます。自動注射器とペン型注射器は、その使いやすさと信頼性から一般に好まれています。一方、無針注射器やウェアラブル注射器は、より侵襲の少ない、あるいはより柔軟な薬物送達方法を求める患者に適しています。

使用法：交差汚染のリスクを回避するために、使い捨ての自己注射薬の使用が増加しています。

ディスポーザブル自己注射器は、利便性、安全性、交差汚染のリスクの低減のために好まれている使い捨て注射器です。使い捨て自己注射器は、短期間の薬物療法を必要とする患者や、注射器のメンテナンスの手間を省くことを優先する患者に選ばれることが多いです。感染症のリスクが高い疾患では使い捨て注射器が好まれます。再使用可能な自己注射器は複数回使用可能なシステムであり、長期間の投薬が必要な慢性疾患の患者に好まれています。再使用可能な自己注射器は、費用対効果が高く、定期的なメンテナンスが必要であり、耐久性に優れた設計となっています。再使用可能な注射器は、長期投薬レジメンに好まれます。使い捨て注射器は、特に長期投薬が必要でない患者にとって、利便性と安全性を提供します。

流通チャネル：オンライン・プラットフォームにおける自己注射薬の新たな浸透

病院薬局は、主に医療施設に直結した入院患者や外来患者を対象としています。入院中に自己注射療法を処方された患者は、多くの場合、病院の薬局から直接、自己注射器具の初回供給を受けています。自己注射器具の使用について専門的な指導を必要とする患者や、手厚いサポートや指導を求める患者は、病院の薬局を好みます。eコマースの台頭は医薬品分野にも及んでおり、オンライン薬局は利便性、慎重さ、低価格を提供しています。オンライン薬局は、すでに自己注射のレジメンに慣れており、宅配を好む患者には特に適しています。利便性を優先する患者、移動や移動に困難がある患者、自己注射のレジメンが安定している患者は、オンライン薬局を高く選ぶ。個人クリニックは、患者一人ひとりに合ったケアを提供し、信頼できるヘルスケアプロバイダーとの一定の継続性を求める患者に対応します。プライベート・クリニックは、一貫したモニタリングと医療従事者のフォローアップが必要な自己注射療法を受けるのに有益です。病院薬局はすぐにアクセスでき、患者教育リソースがあるため、オンライン薬局は利便性と潜在的なコスト削減のため、そして個人クリニックは個別化された継続的ケアのため、それぞれ好まれています。

治療分野への応用：ホルモン問題の治療における自己注射薬の用途拡大

自己注射療法は、関節リウマチやループスを含む自己免疫疾患の治療に極めて重要です。アダリムマブやエタネルセプトを含む生物学的製剤は、自己注射によって投与され、炎症を管理し、病気の進行を修正します。AIDSの管理では、抗レトロウイルス薬の自己注射製剤は、投与回数の少ない選択肢を提供することでアドヒアランスを高める可能性があります。自己注射可能なエピネフリン自動注射器は、重篤なアレルギーを持つ人の命を救う装置です。自己注射薬により、アレルギー反応が起きた場合に直ちに治療を行うことができ、致命的なアナフィラキシーを防ぐことができます。腫瘍患者にとって、顆粒球コロニー刺激因子（G-CSF）などの自己注射薬は、化学療法による好中球減少症の管理に役立ちます。自己注射は頻繁なヘルスケア受診の必要性を軽減し、がん治療の継続性をサポートします。クローン病を含む過敏性腸疾患の治療における自己注射療法は、抗炎症薬や免疫抑制薬を使用し、症状のコントロールや長期寛解の導入に不可欠です。βインターフェロンを含む自己注射薬は、多発性硬化症患者の治療レジメンの主軸であり、症状を管理し、疾患の進行を遅らせるのに役立っています。

乾癬では、自己注射可能な生物学的製剤が免疫系内の特定の経路を標的とし、過剰な炎症反応を抑えます。自己注射可能な緊急用医薬品は、危機に際して迅速に投与できるように設計されており、エピネフリン、グルカゴン、ナロキソン自動注射器に代表されるように、急性のアレルギー反応、重度の低血糖、麻薬の過剰摂取に対する治療薬があります。エピネフリン自己注射器は、生命を脅かす可能性のある重篤なアレルギー反応であるアナフィラキシーショック時の第一の防御手段です。片頭痛の自己注射治療は、片頭痛の症状を迅速に緩和します。自己注射薬は、内服薬よりも片頭痛発作を早く止めることができるため、症状が重い患者や吐き気や嘔吐を経験している患者にとって有益です。ホルモン補充療法に使用される自己注射剤は、テストステロン、エストロゲン、プロゲステロンなどのホルモンを安定的に投与することができ、ホルモン欠乏症の患者やトランスジェンダーの患者に有益です。βインターフェロン自己注射薬は、主に多発性硬化症の治療、炎症の軽減、再発エピソードの頻度の減少に使用されます。エリスロポエチン（EPO）自己注射薬は、慢性腎臓病患者の貧血対策に不可欠です。エリスロポエチン（EPO）自己注射剤は赤血球産生を刺激し、輸血の必要性を減らすのに役立ちます。卵胞刺激ホルモン（FSH）自己注射剤は、不妊治療において重要な役割を果たします。女性では卵巣の卵胞の成長を、男性では精子形成を刺激します。低分子ヘパリン自己注射薬は、長期外来抗凝固療法に使いやすい選択肢を提供するため、血栓症のリスクがある患者の抗凝固療法に一般的に使用されています。自己注射用インスリンは糖尿病管理の基礎となる治療法であり、血糖値や食事摂取量に応じてインスリンを投与できるため、柔軟性があり血糖コントロールが良好です。骨粗鬆症患者にとって、副甲状腺ホルモンの自己注射は、重度の骨粗鬆症の管理に不可欠な新しい骨の成長を刺激することによって、骨密度を改善するのに役立ちます。パーキンソン病患者には、症状の緩和や病気の進行を遅らせる自己注射薬が有効です。

地域別の洞察

南北アメリカの自己注射薬市場は、患者中心のケア、高度な医療インフラ、患者に優しい投与が求められる生物学的製剤の承認取得の増加などが大きな原動力となっています。消費者の間では、利便性に合致した自己注射器を含むセルフケアの選択肢に対する意識が高まっています。在院日数の短縮や薬剤の自己投与を促進する政府の取り組みも、南北アメリカにおける自己注射薬の浸透に寄与しています。欧州連合（EU）では、高齢化、慢性疾患の蔓延、自己管理志向の高まりが自己注射器市場の成長を支えています。EUの厳格な規制の枠組みは、自己注射機器の高い安全基準を保証しています。さらに、EUのいくつかの国では、自己注射の導入を促進するための患者教育プログラムを積極的に実施しています。中東・アフリカでは、ヘルスケア・インフラへの大規模な投資と生活習慣病の増加が、自己注射器市場の有望な成長を示しています。アジア太平洋地域では、急速な経済成長とヘルスケア支出の増加が自己注射薬市場の主な促進要因となっています。政府による医薬品イノベーションの重視と慢性疾患の急増が需要を押し上げています。さらに、技術的に進んだヘルスケアシステムと高齢化社会が、アジア太平洋地域の自己注射器市場を支えています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、自己注射薬市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、自己注射薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.自己注射薬市場の市場規模および予測は？

2.自己注射薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.自己注射薬市場の技術動向と規制枠組みは？

4.自己注射薬市場における主要ベンダーの市場シェアは？

5.自己注射薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患および関節リウマチの急速な蔓延
    • 不妊治療のための自己注射薬の幅広い利用可能性
  • 抑制要因
    • 製品リコールの潜在的リスク
  • 機会
    • 世界中で自己注射薬の政府承認が進行中
    • 自己注射器の技術的進歩
  • 課題
    • 自己注射薬に関連する認識と管理上の課題が限られている
• 市場セグメンテーション分析
  • タイプ：慢性疾患の管理におけるペン型注射器の好感度の高まり
  • 使用法：交差汚染のリスクを回避するために使い捨ての自己注射薬の使用が増えています
  • 配信チャネル：オンラインプラットフォームでの自己注射薬の普及
  • 治療領域の応用：ホルモンの問題を治療するための自己注射薬の応用が拡大中
• 市場動向分析
  • 糖尿病や慢性疾患の増加により、南北アメリカで自己注射薬の必要性が高まっている
  • APAC地域におけるヘルスケアインフラと自己注射薬デバイスのイノベーションへの投資増加
  • EMEA地域における自己注射薬に対する政府による支持承認
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析

第6章 自己注射薬市場：タイプ別

• 自動注射器
• 無針注射器
• ペン型注射器
• ウェアラブルインジェクター

第7章 自己注射薬市場用途別

• 使い捨て
• 再利用可能

第8章 自己注射薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 個人クリニック

第9章 自己注射薬市場治療領域別アプリケーション

• 自己免疫疾患
• 緊急医薬品
• ホルモン補充療法

第10章 南北アメリカの自己注射薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の自己注射薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの自己注射薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • マイクロン・バイオメディカル、針なしワクチン製造のための資金を獲得
  • Enable Injectionsが米国食品医薬品局（FDA）の初の承認を取得
  • アルタビズ、ドラッグデリバリー用の新しい自動注射器プラットフォームを発表
  • FDA、PNH治療薬ペグセタコプランの自己投与用体内注射器を承認
  • シヴィカ、インスリン注射ペンでイプソメッドと提携
  • エイタン・メディカル、ウェアラブル・インジェクター事業の移行を完了
  • Coherus、UDENYCA自動注射器の米国での発売を発表
  • Ypsomedが統合ヒューマンファクターサービスで自己注射デバイスプラットフォームを強化
  • Viridian Therapeutics、ドラッグデリバリーの革新企業Enable Injectionsとの提携を発表
  • 米国FDA、プレフィルドペンを使用した自己投与用Tezspireを承認
  • フィリップス・メディサイズ、医薬品コスト、リスク、市場障壁の低減を目的としたペン型注射器プラットフォームの発売により製品ポートフォリオを拡大

第14章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. SELF-INJECTIONS MARKET RESEARCH PROCESS
• FIGURE 2. SELF-INJECTIONS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL SELF-INJECTIONS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. SELF-INJECTIONS MARKET DYNAMICS
• FIGURE 7. GLOBAL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. SELF-INJECTIONS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. SELF-INJECTIONS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. SELF-INJECTIONS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL SELF-INJECTIONS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL SELF-INJECTIONS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL SELF-INJECTIONS MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL SELF-INJECTIONS MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PEN INJECTORS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PEN INJECTORS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL SELF-INJECTIONS MARKET SIZE, BY WEARABLE INJECTORS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL SELF-INJECTIONS MARKET SIZE, BY WEARABLE INJECTORS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISPOSABLE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISPOSABLE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REUSABLE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REUSABLE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AIDS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AIDS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ALLERGIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ALLERGIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL SELF-INJECTIONS MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL SELF-INJECTIONS MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL SELF-INJECTIONS MARKET SIZE, BY IRRITABLE BOWEL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL SELF-INJECTIONS MARKET SIZE, BY IRRITABLE BOWEL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL SELF-INJECTIONS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL SELF-INJECTIONS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PSORIASIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ANAPHYLACTIC SOCKS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ANAPHYLACTIC SOCKS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL SELF-INJECTIONS MARKET SIZE, BY MIGRAINE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL SELF-INJECTIONS MARKET SIZE, BY MIGRAINE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL SELF-INJECTIONS MARKET SIZE, BY BETA-INTERFERON, BY REGION, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL SELF-INJECTIONS MARKET SIZE, BY BETA-INTERFERON, BY REGION, 2024-2030 (USD MILLION)
• TABLE 63. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 64. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 65. GLOBAL SELF-INJECTIONS MARKET SIZE, BY FOLLICLE STIMULATING HORMONE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 66. GLOBAL SELF-INJECTIONS MARKET SIZE, BY FOLLICLE STIMULATING HORMONE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 67. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HEPARIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 68. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HEPARIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 69. GLOBAL SELF-INJECTIONS MARKET SIZE, BY INSULIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 70. GLOBAL SELF-INJECTIONS MARKET SIZE, BY INSULIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 71. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PARATHYROID HORMONE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 72. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PARATHYROID HORMONE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 73. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PARKINSON'S, BY REGION, 2018-2023 (USD MILLION)
• TABLE 74. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PARKINSON'S, BY REGION, 2024-2030 (USD MILLION)
• TABLE 75. AMERICAS SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 76. AMERICAS SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 77. AMERICAS SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
• TABLE 78. AMERICAS SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
• TABLE 79. AMERICAS SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 80. AMERICAS SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 81. AMERICAS SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
• TABLE 82. AMERICAS SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
• TABLE 83. AMERICAS SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
• TABLE 84. AMERICAS SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
• TABLE 85. AMERICAS SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
• TABLE 86. AMERICAS SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
• TABLE 87. AMERICAS SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
• TABLE 88. AMERICAS SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
• TABLE 89. AMERICAS SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 90. AMERICAS SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 91. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 92. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 93. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
• TABLE 94. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
• TABLE 95. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 96. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 97. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
• TABLE 98. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
• TABLE 99. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
• TABLE 100. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
• TABLE 101. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
• TABLE 102. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
• TABLE 103. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
• TABLE 104. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
• TABLE 105. BRAZIL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 106. BRAZIL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 107. BRAZIL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
• TABLE 108. BRAZIL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
• TABLE 109. BRAZIL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 110. BRAZIL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 111. BRAZIL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
• TABLE 112. BRAZIL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
• TABLE 113. BRAZIL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
• TABLE 114. BRAZIL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
• TABLE 115. BRAZIL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
• TABLE 116. BRAZIL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
• TABLE 117. BRAZIL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
• TABLE 118. BRAZIL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
• TABLE 119. CANADA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 120. CANADA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 121. CANADA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
• TABLE 122. CANADA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
• TABLE 123. CANADA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 124. CANADA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 125. CANADA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
• TABLE 126. CANADA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
• TABLE 127. CANADA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
• TABLE 128. CANADA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
• TABLE 129. CANADA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
• TABLE 130. CANADA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
• TABLE 131. CANADA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
• TABLE 132. CANADA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
• TABLE 133. MEXICO SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 134. MEXICO SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 135. MEXICO SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
• TABLE 136. MEXICO SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
• TABLE 137. MEXICO SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 138. MEXICO SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 139. MEXICO SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
• TABLE 140. MEXICO SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
• TABLE 141. MEXICO SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
• TABLE 142. MEXICO SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
• TABLE 143. MEXICO SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
• TABLE 144. MEXICO SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
• TABLE 145. MEXICO SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
• TABLE 146. MEXICO SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
• TABLE 147. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 148. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 149. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
• TABLE 150. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
• TABLE 151. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 152. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 153. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
• TABLE 154. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
• TABLE 155. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
• TABLE 156. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
• TABLE 157. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
• TABLE 158. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
• TABLE 159. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
• TABLE 160. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
• TABLE 161. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 162. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 163. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 164. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 165. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
• TABLE 166. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
• TABLE 167. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 168. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 169. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
• TABLE 170. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
• TABLE 171. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
• TABLE 172. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
• TABLE 173. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
• TABLE 174. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
• TABLE 175. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
• TABLE 176. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
• TABLE 177. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 178. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 179. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 180. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 181. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
• TABLE 182. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
• TABLE 183. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 184. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 185. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
• TABLE 186. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
• TABLE 187. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
• TABLE 188. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
• TABLE 189. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
• TABLE 190. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
• TABLE 191. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
• TABLE 192. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
• TABLE 193. CHINA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 194. CHINA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 195. CHINA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
• TABLE 196. CHINA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
• TABLE 197. CHINA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 198. CHINA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 199. CHINA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
• TABLE 200. CHINA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
• TABLE 201. CHINA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
• TABLE 202. CHINA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
• TABLE 203. CHINA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
• TABLE 204. CHINA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
• TABLE 205. CHINA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
• TABLE 206. CHINA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
• TABLE 207. INDIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 208. INDIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 209. INDIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
• TABLE 210. INDIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
• TABLE 211. INDIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 212. INDIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 213. INDIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
• TABLE 214. INDIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
• TABLE 215. INDIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
• TABLE 216. INDIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
• TABLE 217. INDIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
• TABLE 218. INDIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
• TABLE 219. INDIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
• TABLE 220. INDIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
• TABLE 221. INDONESIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 222. INDONESIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 223. INDONESIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
• TABLE 224. INDONESIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
• TABLE 225. INDONESIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 226. INDONESIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 227. INDONESIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
• TABLE 228. INDONESIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
• TABLE 229. INDONESIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
• TABLE 230. INDONESIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
• TABLE 231. INDONESIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
• TABLE 232. INDONESIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
• TABLE 233. INDONESIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
• TABLE 234. INDONESIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
• TABLE 235. JAPAN SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 236. JAPAN SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 237. JAPAN SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
• TABLE 238. JAPAN SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
• TABLE 239. JAPAN SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 240. JAPAN SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 241. JAPAN SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
• TABLE 242. JAPAN SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
• TABLE 243. JAPAN SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
• TABLE 244. JAPAN SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
• TABLE 245. JAPAN SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
• TABLE 246. JAPAN SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
• TABLE 247. JAPAN SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
• TABLE 248. JAPAN SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
• TABLE 249. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 250. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 251. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
• TABLE 252. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
• TABLE 253. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 254. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 255. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
• TABLE 256. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
• TABLE 257. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
• TABLE 258. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
• TABLE 259. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
• TABLE 260. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
• TABLE 261. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
• TABLE 262. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
• TABLE 263. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 264. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 265. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
• TABLE 266. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
• TABLE 267. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 268. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 269. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
• TABLE 270. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
• TABLE 271. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
• TABLE 272. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
• TABLE 273. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
• TABLE 274. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
• TABLE 275. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
• TABLE 276. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
• TABLE 277. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 278. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 279. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
• TABLE 280. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
• TABLE 281. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 282. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 283. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
• TABLE 284. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
• TABLE 285. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
• TABLE 286. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
• TABLE 287. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
• TABLE 288. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
• TABLE 289. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
• TABLE 290. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
• TABLE 291. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 292. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 293. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
• TABLE 294. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
• TABLE 295. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 296. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 297. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
• TABLE 298. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
• TABLE 299. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
• TABLE 300. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
• TABLE 301. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
• TABLE 302. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
• TABLE 303. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
• TABLE 304. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
• TABLE 305. TAIWAN SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 306. TAIWAN SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 307. TAIWAN SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
• TABLE 308. TAIWAN SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
• TABLE 309. TAIWAN SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 310. TAIWAN SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 311. TAIWAN SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
• TABLE 312. TAIWAN SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
• TABLE 313. TAIWAN SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
• TABLE 314. TAIWAN SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
• TABLE 315. TAIWAN SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
• TABLE 316. TAIWAN SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
• TABLE 317. TAIWAN SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
• TABLE 318. TAIWAN SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
• TABLE 319. THAILAND SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 320. THAILAND SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 321. THAILAND SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
• TABLE 322. THAILAND SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
• TABLE 323. THAILAND SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 324. THAILAND SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 325. THAILAND SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
• TABLE 326. THAILAND SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
• TABLE 327. THAILAND SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
• TABLE 328. THAILAND SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
• TABLE 329. THAILAND SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
• TABLE 330. THAILAND SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
• TABLE 331. THAILAND SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
• TABLE 332. THAILAND SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
• TABLE 333. VIETNAM SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 334. VIETNAM SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 335. VIETNAM SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
• TABLE 336. VIETNAM SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
• TABLE 337. VIETNAM SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 338. VIETNAM SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 339. VIETNAM SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
• TABLE 340. VIETNAM SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
• TABLE 341. VIETNAM SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
• TABLE 342. VIETNAM SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
• TABLE 343. VIETNAM SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
• TABLE 344. VIETNAM SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-203

[195 Pages Report] The Self-injections Market size was estimated at USD 54.00 billion in 2023 and expected to reach USD 60.64 billion in 2024, at a CAGR 12.72% to reach USD 124.87 billion by 2030.

Self-injections refer to the products used to administer medication to themselves intramuscularly, subcutaneously, or intravenously without the immediate assistance of healthcare professionals. Self-injections are used for treatments that require regular and long-term care, such as insulin for diabetes, hormones for hormone replacement therapy and fertility treatments, and biologics for chronic conditions. Self-injection devices are widely used to increase autonomy and can improve treatment adherence by eliminating the need for healthcare provider administration. An elevating prevalence of chronic diseases, the need for home-based healthcare, advancements in drug delivery technology, and a growing patient preference for self-administration have improved the usage of self-injections in recent years. However, the requirement for significant investment in research and development, patient safety and comfort concerns, and the need for cold chain storage and logistics for biologics limit the product penetration of self-injections. Recognition of digitization and patient-centricity leads to opportunities for integrating smart technology into self-injection devices. Innovations focusing on connectivity can provide data collection, patient monitoring, and adherence tracking, guiding personalized treatment modalities for self-injections. Moreover, the supportive government approvals for self-injections are further expanding the scope of the market.

Type: Rising preference for pen injectors to manage chronic diseases

Auto-injectors are designed for convenient use and can administer a precise dose of medication with minimal training. Auto-injectors are used for the delivery of life-saving drugs in emergencies. The need-based preference for auto-injectors is high among patients who require immediate and reliable administration of drugs, often without the assistance of healthcare professionals. Needle-free injectors offer an alternative to traditional syringe injections, removing the need for needles. Needle-free injectors use a high-pressure, narrow jet of the injection liquid to penetrate the skin to deliver the medication. Individuals with needle phobia mainly prefer needle-free injectors or those who require frequent injections, such as diabetic patients who may otherwise experience needle fatigue. Pen injectors are widely used to manage chronic diseases, allowing insulin or growth hormone self-administration. Pen injectors are portable, discreet, and relatively easy to use, appealing to patients who need to administer medication regularly while maintaining an active lifestyle. Wearable injectors, also known as patch pumps, are devices that adhere to the patient's body and provide continuous or controlled delivery of drugs over an extended period. Wearable injectors are primarily used by patients who require long-term therapies. Auto-injectors and pen injectors are generally favored for their ease of use and reliability. In contrast, needle-free and wearable injectors cater to patients seeking a less invasive or more flexible approach to medication delivery.

Usage: Growing use of disposable self-injections to avoid the risk of cross-contamination

Disposable self-injection devices are single-use injectors preferred for their convenience, safety, and the reduced risk of cross-contamination. Disposable self-injection devices are often chosen by patients requiring short-term medication regimens or those prioritizing the ease of not having to manage the maintenance of the device. Disposable injectors are preferred for diseases with a high risk of infection transmission. Reusable self-injection devices are multi-use systems that offer cost benefits over time and are favored by patients with chronic conditions requiring long-term medication delivery. Reusable self-injection devices are cost-effective, necessitate regular maintenance and are designed for durable use. Reusable injectors are preferred for long-term medication regimens. Disposable injectors offer convenience and safety, especially for patients not requiring long-term medication.

Distribution Channel: Emerging penetration of self-injections on online platforms

Hospital pharmacies primarily serve inpatients and outpatients directly connected to medical facilities. Patients who have been prescribed self-injection therapies during a hospital stay often receive their initial supply of self-injection equipment directly from the hospital pharmacy. Patients requiring specialized instruction on the use of self-injection devices or seeking high-touch support and guidance prefer hospital pharmacies. The rise of eCommerce has extended to the pharmaceutical field, with online pharmacies offering convenience, discretion, and lower prices. Online pharmacies are particularly well-suited for those who are already familiar with their self-injection regimen and prefer home delivery. Patients who prioritize convenience, have mobility and transportation challenges or have a stable self-injection regime choose online pharmacies highly. Private clinics offer personalized care and cater to patients looking for a certain continuity of care with a healthcare provider they trust. Private clinics can be beneficial for receiving self-injection therapies that require consistent monitoring and follow-up with the healthcare practitioner. Hospital pharmacies are preferred for their immediate accessibility and patient education resources, online pharmacies for convenience and potential cost savings, and private clinics for personalized, ongoing care.

Therapeutic Areas Application: Growing applications of self-injections to treat hormonal issues

Self-injection therapies are pivotal for the treatment of autoimmune diseases, including rheumatoid arthritis and lupus. Biological agents, including adalimumab and etanercept, are administered via self-injection to manage inflammation and modify disease progression. In the management of AIDS, self-injectable formulations of antiretroviral drugs may enhance adherence by providing less frequent dosing options. Self-injectable epinephrine auto-injectors are life-saving devices for individuals with severe allergies. Self-injections allow for immediate treatment in the case of an allergic reaction, preventing potentially fatal anaphylaxis. For oncology patients, self-injectables such as granulocyte colony-stimulating factors (G-CSF) help manage chemotherapy-induced neutropenia. Self-administration can mitigate the need for frequent healthcare visits and support the continuity of cancer treatment. Self-injectable therapies in the treatment of irritable bowel disorders, including Crohn's disease, involve anti-inflammatory and immunosuppressive drugs, which are vital in controlling symptoms and inducing long-term remission. Self-administered injectable medications, including beta-interferon, are a mainstay in the treatment regimen for multiple sclerosis patients to assist in managing symptoms and slow the progression of the disorder.

In psoriasis, self-injectable biologics target specific pathways within the immune system to reduce the overactive inflammatory response. Self-injectable emergency drugs, designed for rapid administration in crises, include treatments for acute allergic reactions, severe hypoglycemia, and narcotic overdoses, exemplified by epinephrine, glucagon, and naloxone auto-injectors, respectively. Epinephrine auto-injectors are the first line of defense during anaphylactic shocks, a severe, potentially life-threatening allergic reaction. Self-injectable treatments for migraines offer rapid relief of migraine symptoms. Self-injections can abort migraine attacks more quickly than oral medications, which is beneficial for patients with severe symptoms or those experiencing nausea and vomiting. Self-injectables used in hormone replacement therapies provide a consistent delivery method for hormones, including testosterone, estrogen, or progesterone, benefiting patients with hormonal deficiencies or in transgender care. Beta-interferon self-injections are used primarily to treat multiple sclerosis, reduce inflammation, and decrease the frequency of relapse episodes. Erythropoietin (EPO) self-injectables are essential for patients with chronic kidney disease to combat anemia. Erythropoietin (EPO) self-injectables stimulate red blood cell production and help to reduce the need for blood transfusions. Self-injectable follicle-stimulating hormone (FSH) plays a crucial role in fertility treatments. It stimulates ovary follicle growth in women and spermatogenesis in men. Low molecular weight heparin self-injections are commonly used for anticoagulation in patients at risk for thrombosis to provide an easy-to-use option for long-term outpatient anticoagulation therapy. Self-injected insulin is a cornerstone treatment for diabetes management that allows individuals to dose insulin according to their blood glucose levels and dietary intake, providing flexibility and better glycemic control. For osteoporosis patients, self-injected parathyroid hormone can help improve bone density by stimulating new bone growth, an essential aspect of managing severe osteoporosis. Parkinson's disease patients may benefit from self-injectable medications that can provide symptomatic relief or slow disease progression.

Regional Insights

The self-injections market in the Americas is driven by a strong emphasis on patient-centric care, advanced healthcare infrastructure, and an increase in biologic drug approvals that require patient-friendly administration. Consumers are becoming increasingly aware of self-care options, including self-injection devices, which align with convenience. Government initiatives to reduce hospital stays and promote self-administration of medication also contribute to the penetration of self-injections in the Americas. In the European Union, market growth for self-injection devices is supported by an aging population, the prevalence of chronic diseases, and a strong inclination toward self-management of these conditions. The EU's rigorous regulatory framework ensures high safety standards for self-injection devices. Furthermore, several EU countries have been active in running patient education programs to encourage the adoption of self-injection practices. In the Middle East and Africa, substantial investments in healthcare infrastructure and an increasing incidence of lifestyle-related diseases show promising growth for the self-injections market. In the Asia-Pacific region, rapid economic growth and increased healthcare expenditure are major drivers for the self-injections market. The government's emphasis on pharmaceutical innovation and the surging prevalence of chronic diseases are boosting demand. Furthermore, a technologically advanced healthcare system and an aging population enable the market for self-injection devices in the Asia Pacific.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Self-injections Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Self-injections Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Self-injections Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Antares Pharma, Inc. by Halozyme, Inc., AstraZeneca plc, Baxter International, Inc., Becton, Dickinson and Company, Credence MedSystems, Inc., DALI Medical Devices Ltd., Eli Lilly and Company, Enable Injections, Inc., Gerresheimer AG, GlaxoSmithKline plc, Insulet Corporation, Johnson & Johnson Services, Inc., Medmix AG by Sulzer Ltd., Merck KGaA, Molex LLC by Koch Industries, Inc., Mylan N.V. by Viatris Inc., Novo Nordisk A/S, Owen Mumford Limited, PenJet Corporation, Pfizer Inc., PharmaJet, Inc., Recipharm AB, Sanofi S.A., SCHOTT AG, SHL Medical AG, Terumo Corporation, Teva Pharmaceutical Industries Ltd., West Pharmaceutical Services, Inc., and Ypsomed Group.

Market Segmentation & Coverage

This research report categorizes the Self-injections Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
  • Auto-Injectors
  • Needle-free Injectors
  • Pen Injectors
  • Wearable Injectors

• Usage
  • Disposable
  • Reusable

• Distribution Channel
  • Hospital Pharmacies
  • Online Pharmacies
  • Private Clinics

• Therapeutic Areas Application
  • Autoimmune Diseases
    • AIDS
    • Allergies
    • Cancer
    • Irritable Bowel Disorders
    • Multiple Sclerosis
    • Psoriasis

• Emergency Drugs
  • Anaphylactic Socks
  • Migraine

• Hormone Replacement Therapies
  • Beta-Interferon
  • Erythropoietin
  • Follicle Stimulating Hormone
  • Heparin
  • Insulin
  • Parathyroid Hormone
  • Parkinson's
• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Self-injections Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Self-injections Market?

3. What are the technology trends and regulatory frameworks in the Self-injections Market?

4. What is the market share of the leading vendors in the Self-injections Market?

5. Which modes and strategic moves are suitable for entering the Self-injections Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rapid prevalence of chronic diseases and rheumatoid arthritis
    • 5.1.1.2. Wide availability of self-injections for fertility treatments
  • 5.1.2. Restraints
    • 5.1.2.1. Potential risk of product recall
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing government approvals for self-injections worldwide
    • 5.1.3.2. Technological advancements in self-injection devices
  • 5.1.4. Challenges
    • 5.1.4.1. Limited awareness and administration challenges associated with self-injections
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Rising preference for pen injectors to manage chronic diseases
  • 5.2.2. Usage: Growing use of disposable self-injections to avoid the risk of cross-contamination
  • 5.2.3. Distribution Channel: Emerging penetration of self-injections on online platforms
  • 5.2.4. Therapeutic Areas Application: Growing applications of self-injections to treat hormonal issues
• 5.3. Market Trend Analysis
  • 5.3.1. Rising incidents of diabetes and chronic diseases creating need for self-injections in the Americas
  • 5.3.2. Growing investment in healthcare infrastructure and innovation in self-injections devices in APAC region
  • 5.3.3. Supportive government approvals for self-injections in the EMEA region
• 5.4. Cumulative Impact of High Inflation
• 5.5. Porter's Five Forces Analysis
  • 5.5.1. Threat of New Entrants
  • 5.5.2. Threat of Substitutes
  • 5.5.3. Bargaining Power of Customers
  • 5.5.4. Bargaining Power of Suppliers
  • 5.5.5. Industry Rivalry
• 5.6. Value Chain & Critical Path Analysis
• 5.7. Regulatory Framework Analysis

6. Self-injections Market, by Type

• 6.1. Introduction
• 6.2. Auto-Injectors
• 6.3. Needle-free Injectors
• 6.4. Pen Injectors
• 6.5. Wearable Injectors

7. Self-injections Market, by Usage

• 7.1. Introduction
• 7.2. Disposable
• 7.3. Reusable

8. Self-injections Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Private Clinics

9. Self-injections Market, by Therapeutic Areas Application

• 9.1. Introduction
• 9.2. Autoimmune Diseases
• 9.3. Emergency Drugs
• 9.4. Hormone Replacement Therapies

10. Americas Self-injections Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Self-injections Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Self-injections Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Micron Biomedical Receives Funds To Produce Needle-Free Vaccines
  • 13.3.2. Enable Injections Receives First U.S. Food and Drug Administration (FDA) Approval
  • 13.3.3. Altaviz introduces New Auto-Injector Platform For Drug Delivery
  • 13.3.4. FDA Approves On-Body Injector for Self Administration of Pegcetacoplan for PNH
  • 13.3.5. Civica Partners With Ypsomed For Insulin Injection Pen
  • 13.3.6. Eitan Medical Completes Transition of Wearable Injectors Business
  • 13.3.7. Coherus Announces U.S. Launch of UDENYCA Autoinjector
  • 13.3.8. Ypsomed Enhances Self-Injection Device Platforms With Integrated Human Factors Services
  • 13.3.9. Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
  • 13.3.10. US FDA Approves Tezspire For Self-Administration Using Pre-Filled Pen
  • 13.3.11. Phillips-Medisize Expands Product Portfolio with Launch of a Pen Injector Platform Designed to Lower Pharma Costs, Risks and Market Barriers

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio